30 closest matches · ranked by relevance
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Responder Rate — 60.7; 63.6 percentage of responders
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Relapse of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms — 3; 12 Participants
CIDP · Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Muscle Strength
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Efficacy Endpoint: Responder Rate at End of Study — 32 Participants — p=<0.0001
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Epoch 1: Relapse Rate — 31.4; 9.7 percentage of participants — p==0.0045
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Number of Adverse Events (AEs) Per Infusion — 0.032 Adverse events per infusion
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary: Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) — 66.5 percentage of participants
Primary Immunodeficiency
Primary: Annual Rate of Occurrence of Serious Bacterial Infections (SBI) — 0; 0.01; 0; 0.03 Rate of events per subject per year
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality — 76; 20 Participants
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Change From Baseline to Week 13 (Day 85) in Inflammatory Rasch-built Overall Disability Scale (iRODS) Score — 0.234; 0.181 score on a scale (logits)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 10; 10 Participants
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.70; -1.81 score on a scale
Primary Immunodeficiency Diseases (PID)
Primary: Validated Acute Serious Bacterial Infection (VASBI) Rate — 0.025 Estimated infections/year — p=<0.0001
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.50; -1.35 score on a scale
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Primary Immunodeficiency (PID)
Primary: Total Serum IgG Trough Levels — 7.97 g/L
Primary Immunodeficiency Disease
Primary: Incidence Rate of Acute Serious Bacterial Infections (ABSIs) — 0.0; 0.0 infections per participant-year
Primary Immune Deficiency
Primary: Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population) — 0.00 SBIs per subject year
Primary Immunodeficiency Diseases (PID)
Primary: Rate of Acute Serious Bacterial Infections Per Year (ASBI) — 0.012 Estimated infections/ year — p=<0.0001
Purpura, Thrombocytopenic, Idiopathic
Primary: Free Hemoglobin — 13.057; 12.371 g/dL
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient
Breast Cancer · Peripheral Neuropathy, Secondary to Drugs or Chemicals
Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053
Agammaglobulinemia · IgG Deficiency · Common Variable Immunodeficiency
Primary: The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs). — 0.073; 0.141; 0.150 Proportion of infusions
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm